drugset
drugset / Trial / NCT02072213

A PK Study GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers

NCT02072213 ↗

Phase 1 Completed 36 enrolled GL Pharm Tech Corporation
RandomizedCrossoverOpen-labelBasic science

Summary

Study to Investigate The Pharmacokinetics of GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers

Timeline

Start
2013-08
Primary completion
2014-01
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tamsulosin Other / unclassified 0.4 mg —

Indications

No indication recorded.